CoorsTek Bioceramics has secured a significant legal victory in its ongoing trademark dispute with CeramTec GmbH over the use of the color pink for ceramic hip components. The German Federal Patent Court (GFPC) upheld the cancellation of CeramTec's trademark in Germany, ruling that the application had been filed in bad faith with the intention of extending an expiring patent monopoly and excluding competitors from the market. The decision, announced on November 5, 2026, marks another chapter in a multi-jurisdictional battle over trademark rights to a color that has become synonymous with a specific type of ceramic hip implant.
The implications of this ruling extend beyond the courtroom. For CoorsTek Bioceramics, the decision reinforces its ability to market its ceramic hip replacement components, including its Permallon orthopaedic ceramics, in Germany without the threat of trademark infringement claims. The company has now secured favorable rulings in France and the United States, creating a more consistent legal landscape across key markets. According to the full announcement, which can be accessed by clicking here, the GFPC's finding of bad faith is particularly notable because it suggests CeramTec attempted to use trademark law to achieve what patent law no longer allowed—a monopoly over pink ceramic hip components.
For the orthopaedic industry, the ruling could signal a shift toward greater competition in the ceramic hip component market. CeramTec has appealed the decision, so the legal fight is not yet over. However, CoorsTek points to its continued court wins and OEM regulatory clearances as evidence that a more competitive supply chain is emerging. This matters because competition in the medical device sector can drive innovation and potentially lower costs for implant manufacturers and, ultimately, healthcare systems. The ruling also clarifies that trademark protection cannot be used to perpetuate market exclusivity beyond the life of a patent, a principle that could influence future disputes involving color trademarks in medical devices.
CoorsTek Bioceramics, a wholly owned subsidiary of CoorsTek, has sold over six million ceramic components for clinical use since 2005 and focuses on ceramic bearing surfaces for total joint arthroplasty. The company's Permallon ceramics are at the center of its efforts to gain market share in the orthopaedic ceramics space. The German ruling, while subject to appeal, provides CoorsTek with a stronger footing to promote its products as a viable alternative in a market that has been shaped by trademark exclusivity. The outcome of CeramTec's appeal will be closely watched by industry observers, as it could further define the boundaries of trademark rights in the medical device field.
